Inhalation of ACE2 as a therapeutic target on sex-bias differences in SARS-CoV-2 infection and variant of concern

ACE2吸入疗法作为治疗SARS-CoV-2感染中性别差异及相关变异株的潜在靶点

阅读:1
作者:Yu Onodera ,Jady Liang ,Yuchong Li ,Bryan Griffin ,Thenuka Thanabalasingam ,Cong Lu ,JiaYi Zhu ,Mingyao Liu ,Theo Moraes ,Wenhua Zheng ,Jasmin Khateeb ,Julie Khang ,Yongbo Huang ,Mirjana Jerkic ,Masaki Nakane ,Andrew Baker ,Beverley Orser ,Ya-Wen Chen ,Gerald Wirnsberger ,Josef M Penninger ,Ori D Rotstein ,Arthur S Slutsky ,Yimin Li ,Samira Mubareka ,Haibo Zhang

Abstract

Despite similar infection rates, COVID-19 has resulted in more deaths in men than women. To understand the underlying mechanisms behind this sex-biased difference in disease severity, we infected K18-human angiotensin converting enzyme 2 (ACE2) mice of both sexes with SARS-CoV-2. Our study revealed a unique protein expression profile in the lung microenvironment of female mice. As a result, they were less vulnerable to severe infection, with higher ACE2 expression and a higher estrogen receptor α (ERα)/androgen receptor (AR) ratio that led to increased antiviral factor levels. In male mice, inhaling recombinant ACE2 neutralized the virus and maintained the ERα/AR ratio, thereby protecting the lungs. Our findings suggest that inhaling recombinant ACE2 could serve as a decoy receptor against SARS-CoV-2 and protect male mice by offsetting ERα-associated protective mechanisms. Additionally, our study supports the potential effectiveness of recombinant ACE2 therapy in human lung organoids infected with the Delta variant.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。